No profile data available.
Zoetis Inc. (ZTS) is a healthcare company in the animal healthcare items industry, based in Parsippany, United States, with about 14,500 full-time employees.
It reported revenue of $9.47 billion for fiscal year 2025, and net income of $2.67 billion. In Q2 2026 (the quarter ended June 30, 2026) revenue was $2.47 billion. Its largest business segment, United States, brought in 55% of segment revenue in fiscal year 2025; United States was the largest region with 55%. Its market capitalization was $30.91 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Zoetis reported $9.47 billion in revenue for fiscal year 2025. In Q2 2026 revenue was $2.47 billion.
United States, with $5.10 billion or 55% of segment revenue in fiscal year 2025. Next: International (45%).
United States: 55% of revenue by region in fiscal year 2025, followed by Other Emerging Markets (10%).
$30.91 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (animal healthcare items) include Idexx Laboratories, Inc. (IDXX), Elanco Animal Health Incorporated (ELAN), Phibro Animal Health Corporation (PAHC), ImmuCell Corporation (ICCC).